寿尔智颗粒制备及治疗血管性痴呆80例临床观察

Preparation of Shouerzhi granule and clinical observation on treating 80 cases of vascular dementia

目的:评价寿尔智颗粒治疗血管性痴呆的临床效果和安全性。方法:收集80例血管性痴呆患者随机分为治疗组40例和对照组40例。两组均常规治疗,对照组在此基础上口服西药吡拉西坦片0.8 g/次,3次/d;治疗组在此基础上口服寿尔智颗粒,6 g/次,3次/d,分早中晚3次口服。两组均治疗30 d,观察两组临床疗效、中医证候、治疗前后认知功能、行为能力性质及检测治疗前后两组病例血液流变学指标;评价寿尔智颗粒治疗血管性痴呆症的有效性和安全性。结果:1两组综合疗效:治疗组40例,总有效率为70.0%;对照组40例,总有效率为45.0%。经统计学处理,治疗组疗效明显高于对照组,(P<0.01)。2中医证候疗效比较:治疗组总有效率65.0%,对照组总有效率30.0%;经统计学处理,治疗组疗效明显高于对照组(P<0.01)。3治疗组能改善MMSE、HDS、FAQ量表积分,改善血液粘稠度,而且未见毒副作用。结论:寿尔智颗粒治疗血管性痴呆的临床疗效显著,且无明显毒副作用,无不良反应,为中医药治疗血管性痴呆的疗效提供了科学依据。

Objective： To evaluate clinical efficacy and safety of Shouerzhi particles on vascular dementia. Method： 80 vascular dementia patients were randomly divided into a treatment group of 40 patients and the control group of 40 patients. Both groups were given conventional treatment, oral medicine; Treatment group was treated with Shouerzhi particles more orally. Result： ①Comprehensive efficacy in the two groups： the treatment group 40 cases, total effeciciency was 70.0%; control group, 40 cases, total efficiency was 45.0%. Statistically, the treatment group was significantly higher,（P〈0.01）.②Comparison of efficacy of TCM syndrome： the treatment group, the total efficiency of 65.0% in the control group, the total efficiency of 30.0%（P〈0.01）. ③in the treatment group, it can improve MMSE, HDS, FAQ scale integration, improve blood viscosity, and no side effects. Conclusion： Clinical efficacy of Shouerzhi particle on vascular dementia was significant, and no significant side effects, no adverse reactions, can provide a scientific basis for TCM treatment.